Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
about
Heparin-induced thrombocytopenia: an updateHITlights: a career perspective on heparin-induced thrombocytopeniaPlatelet activation in bypass surgery for critical limb ischemiaHeparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatmentImmune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopeniaHeparin-induced thrombocytopenia thrombosis after cardiac surgery. A case report.Newer strategies for the treatment of heparin-induced thrombocytopenia.Determination of heparin-induced IgG antibody in heparin-induced thrombocytopenia type II.Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia.Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation.Aprotinin and organon 10172: a successful combination for coronary artery bypass surgery complicated by heparin-induced thrombocytopenia.Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia.Laboratory diagnosis of heparin-induced thrombocytopenia: advantages of a functional flow cytometric test in comparison to the heparin-induced platelet-activation test.Heparin-induced thrombocytopenia: natural history, diagnosis, and management.Drug-induced and drug-dependent immune thrombocytopenias.Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays.Delayed thrombocytopenia following abciximab therapy.Heparin-induced thrombocytopenia: detection of antiheparin/PF4 antibodies by means of heparin/PF4-coated beads and flow cytometry.On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulantsAcute myocardial infarction caused by delayed heparin-induced thrombocytopenia and acute immunoreaction due to re-exposure to heparin in a systemic lupus erythematosus patient with HIT antibodies.Prevalance of heparin-dependent platelet-activating antibodies in preterm newborns after exposure to unfractionated heparin.[Thrombocytopathy and blood complications in uremia].Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.84-year-old woman with hemodialysis-associated shortness of breath.Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes.Dural Sinus Thrombosis Complicated with Heparin Induced Thrombocytopenia and Thrombosis (HITT).Low allergenic potential with fondaparinux: results of a prospective investigation.A painful HIT.Heparin-induced thrombocytopenia: present and future.Successful preemptive renal retransplantation in a patient with previous acute graft loss secondary to HIT type II: a case report and review of literature.Heparin platelet factor 4 antibody positivity in pseudothrombocytopenia.HIT paradigms and paradoxes.Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature.PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.Heparin-induced thrombocytopenia in a hemodialysis patient treated with fondaparinux: nephrologists between two fires.Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.Protamine-induced immune thrombocytopenia.
P2860
Q24815767-FE8BA35C-EDF2-433B-8AF8-23E8CA8642B8Q26828351-C10CBE6F-2FA7-400B-AD65-1C4EED3A0776Q28219676-B8AAE29A-C48D-419A-9AD2-60DF2018A9FBQ28362737-8732510F-1933-486A-AFC8-A935372ECC0BQ30483035-B4F0F50B-3396-4DCF-AB1E-CDEA75B79909Q30840169-10DF3C14-063E-4703-868F-E876465EB34EQ31440116-4395EBEC-C02C-4ABF-B7F8-14813571A235Q33327972-B5179F8E-2414-4022-8DC5-ACF4C10FF9C8Q33328496-460D3B1F-AE7C-438D-AE30-9979258EF110Q33329858-D6FDE494-AD8D-4614-88CE-67FEADE30D41Q33332774-471090C9-1766-42B3-92E1-E39F7C848ABBQ33335619-127DBC2A-86DA-47CE-A796-BCAF795C8652Q33337297-FFB34818-4035-429F-9E29-67CE738D4F7FQ33337523-B3EAFF95-FB59-4F26-B7A9-3109B53064B8Q33338785-733A55C1-9589-4154-8E94-96B2986178B6Q33339739-BA2E8EC8-4184-4E8A-968C-F4B9DBF57634Q33340783-497750CB-A61A-4C57-BDAC-24EC4F6CFC41Q33341379-5CA33866-41D4-4785-B52B-DFD785EE6D28Q33342589-26860AF5-5A7C-43DD-AF15-EDE2352E5FA8Q33342898-B0D2A898-1902-4665-A98E-58313B656272Q33347011-9BEF3E3A-3059-48B9-BE3D-8ACF90EC51C4Q33349870-30DB9D10-C4A5-477F-BF7C-6E2725C1011FQ33357908-C87530CE-7D0B-4195-98D7-BA5D3244F956Q33363358-3042308F-C70C-4087-AAA2-178EFB3A5DA9Q33371562-9CFABD80-86FD-4BD8-BAF1-A642CF444E9BQ33380931-AADD9ACE-415B-4214-B92E-9FB4E117B8E6Q33383045-4C64D74B-A6B8-407C-98F9-46DC5A21947BQ33388783-09732B73-5B00-471E-B542-1A7221A903E7Q33390482-4AAB13DE-38C8-41AB-91FC-39630DE55368Q33391886-6AAA741F-C4E9-4795-91FE-65D2C01E4126Q33393585-97E801DB-3FBB-4DA9-8029-4AD89EEC7EA7Q33394188-996EED14-9AC6-44A7-B3F1-377CAB996866Q33394592-4B146D8C-CD81-4EF7-B385-57BA86C747DFQ33395386-23071D81-A4C3-4A3D-8E0D-563EB2925535Q33396313-0B9F5F21-B3A4-48F9-9553-658A1882A3E1Q33398271-3C8CEDAD-F9A4-4FC1-9388-C9E31532D358Q33400120-8DC30DCF-5660-4B2F-8C6B-A58FE20C163DQ33401438-F99A4472-92FB-48A7-AC1E-8090EB151E23Q33401466-CFF68A81-7CDF-4A11-8C1C-11EB61CCE36EQ33405699-E6A619FD-31FB-4B0D-B5A9-D678983310B6
P2860
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Antibodies from patients with ...... or bound to endothelial cells
@ast
Antibodies from patients with ...... or bound to endothelial cells
@en
Antibodies from patients with ...... or bound to endothelial cells
@nl
type
label
Antibodies from patients with ...... or bound to endothelial cells
@ast
Antibodies from patients with ...... or bound to endothelial cells
@en
Antibodies from patients with ...... or bound to endothelial cells
@nl
prefLabel
Antibodies from patients with ...... or bound to endothelial cells
@ast
Antibodies from patients with ...... or bound to endothelial cells
@en
Antibodies from patients with ...... or bound to endothelial cells
@nl
P2093
P2860
P921
P356
P1476
Antibodies from patients with ...... or bound to endothelial cells
@en
P2093
P2860
P356
10.1172/JCI116987
P407
P577
1994-01-01T00:00:00Z